We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.90 | -5.45% | 32.95 | 33.00 | 33.85 | 34.75 | 32.95 | 34.25 | 584,830 | 16:20:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -16.98 | 99.08M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/8/2022 12:49 | In addition Rather than adding to a market's store of useful information, short-and-distort traders pollute it with false claims in an effort to provoke shareholders to sell, driving the share price lower. As with other market manipulation schemes, short-and-distort often uses social media, taking advantage of the anonymity it offers and the ease with which misleading claims can spread online You will note LBO/liambooth has posted 24/7 for over a year | j777j | |
16/8/2022 12:49 | key Takeaways Short-and-distort is an illegal market manipulation scheme that involves shorting a stock and then spreading false information in an attempt to drive down its price. The short-and-distort is the inverse of the better known and also illegal pump-an-dump tactic. Negative opinions about a stock are a constitutionally protected speech, as distinct from false claims spread for profit as in a short-and-distort manipulation To protect against such schemes, research the stocks you own to more easily discern false claims, and try not to overreact to dramatic price moves in response to unverified information Anyone think LBO is not a paid deramper? Hahahahahha | j777j | |
16/8/2022 12:48 | She does bang on with her BS | j777j | |
16/8/2022 12:47 | Furthermore it listed over 20 years ago and all its products have failed to date and still has Zero revenues. And now its just left with a medical device gel made of just alcohol and water with no patent and claiming to be a blockbuster treatment for Erectile Dysfunction! LOL | lbo | |
16/8/2022 12:46 | In addition Rather than adding to a market's store of useful information, short-and-distort traders pollute it with false claims in an effort to provoke shareholders to sell, driving the share price lower. As with other market manipulation schemes, short-and-distort often uses social media, taking advantage of the anonymity it offers and the ease with which misleading claims can spread online You will note LBO/liambooth has posted 24/7 for over a year | j777j | |
16/8/2022 12:45 | Key Takeaways Short-and-distort is an illegal market manipulation scheme that involves shorting a stock and then spreading false information in an attempt to drive down its price. The short-and-distort is the inverse of the better known and also illegal pump-an-dump tactic. Negative opinions about a stock are a constitutionally protected speech, as distinct from false claims spread for profit as in a short-and-distort manipulation To protect against such schemes, research the stocks you own to more easily discern false claims, and try not to overreact to dramatic price moves in response to unverified information Anyone think LBO is not a paid deramper? Hahahahahha | j777j | |
16/8/2022 12:44 | Furthermore When opinions give way to falsehoods in the name of a personal gain from a stock's decline, that's something the U.S. Securities and Exchange Commission (SEC) calls "short-and-distort," an illegal market manipulation scheme | j777j | |
16/8/2022 12:44 | Key takeaway! You are ramping on a BB called 'Futura a winner for 2015' and its 2022!ROFLMAO | lbo | |
16/8/2022 12:42 | What is most compelling is LBO has been posting non stop 24/7 for over a year Now who believes he is not a paid deramper? HAHAHAHA | j777j | |
16/8/2022 12:42 | KEY TAKEAWAYS Short-and-distort is an illegal market manipulation scheme that involves shorting a stock and then spreading false information in an attempt to drive down its price. The short-and-distort is the inverse of the better known and also illegal pump-an-dump tactic. Negative opinions about a stock are a constitutionally protected speech, as distinct from false claims spread for profit as in a short-and-distort manipulation To protect against such schemes, research the stocks you own to more easily discern false claims, and try not to overreact to dramatic price moves in response to unverified information. | j777j | |
16/8/2022 12:41 | Yet no mention of it on its website? No launch still? No official launch date even? AllTrinity research said in a recent note no launch until 'probably 2023'? I wonder why only 'probably'?Who remembers the same game with CSD500 and SSL/Reckitt and then Church & Dwight!? LOL | lbo | |
16/8/2022 12:38 | Also of great note KEY TAKEAWAYS Short-and-distort is an illegal market manipulation scheme that involves shorting a stock and then spreading false information in an attempt to drive down its price. The short-and-distort is the inverse of the better known and also illegal pump-an-dump tactic. Negative opinions about a stock are a constitutionally protected speech, as distinct from false claims spread for profit as in a short-and-distort manipulation To protect against such schemes, research the stocks you own to more easily discern false claims, and try not to overreact to dramatic price moves in response to unverified information. | j777j | |
16/8/2022 12:35 | Tried ,tested and about to become the fastest ever selling OTC topical product for ED Fasten seatbelts | j777j | |
16/8/2022 12:34 | Excellent company that sees the potential for the product | j777j | |
16/8/2022 12:27 | Seems the rampers cant even keep up with their own lies! As Glavey pointed outGlavey - 13 Aug 2022 - 05:26:23 - 12667 of 12716How can there be a "short squeeze" if there are no significant short positions?https://se | lbo | |
16/8/2022 12:23 | And what happened to all the revenue from the great deals with Ansell on PET500!? It even was on sale in Walmart and Amazon. Or with CSD500 and all the deals that were signed on it? Where were the royalties from the deals with Kabey Pharmaceuticals and Bizzy Diamond? How long has Med3000 had a CE mark now? How long ago was the Cooper deal? Will shareholders be waiting as long as they were for Reckitt and Church & Dwight? Who then both walked away themselves! LOL | lbo | |
16/8/2022 12:22 | When the pain becomes too much and the short squeeze begins the share price could double in short shrift as everyone becomes a buyer See you in the 60's next. | j777j | |
16/8/2022 12:18 | Cooper Licensing Agreement Under the terms of the agreement, Cooper will commercialise MED3000 in the EEA, United Kingdom and Switzerland as a clinically proven, safe and fast-acting treatment for ED available without the need for a doctor’s prescription. Futura will receive an initial upfront payment, as well as undisclosed cumulative sales milestone payments and will manufacture and supply the product (through its 3rd party contract manufacturers) for the EEA, United Kingdom and Switzerland to Cooper. The agreement is for an initial term of five years complying with EU competition law. Futura will remain Legal Manufacturer1 and be responsible for supply of MED3000 through its 3rd party contract manufacturers. MED3000 is Futura’s breakthrough, topical gel formulation for treatment of ED. It has the potential to become the first globally available, clinically proven, OTC treatment for ED and has already been approved as Medical Device Class IIb according to MDR regulation. Additionally, specific regulatory approval for the Great Britain market post-Brexit was granted in April 2022. Hugely successful companies like Cooper don't make moves unless they are convinced. They are the leaders in OTC products | j777j | |
16/8/2022 12:16 | Cooper, based in Paris, France is an international independent selfcare organisation with main presence in Europe that is active in the Over the Counter (“OTC”) consumer healthcare market with the development, manufacturing, selling and marketing of a diverse range of selfcare products (e.g medicines, medical devices, biocides, cosmetics and food supplements) under its own or licensed well-known brands. Commercial Highlights: · Futura eligible to receive initial upfront payments, as well as undisclosed cumulative sales milestone payments · Cooper to pay an agreed price to Futura for the manufacture and supply of MED3000 by Futura’s third party contractors · Cooper will be responsible for all launch and marketing expenses · Initial licence agreement term of five years. This complies with EU competition law that limits deal terms to five years Big Player!!! | j777j | |
16/8/2022 12:11 | Which brings us back to the non obviousness and prior art patent issues and competitors using the Voltaren vehicle alcohol and water gel to launch an equivalent evaporative cooling gel. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial product Long standing shareholders learned from Futura what clauses have been in previous deals that favour their partners just to get the deals signed and announced. But allows the partners to never have to launch or if they do launch never have to pay any real royalties. And even just hand back the rights with no real penalties after sitting on the rights and running down any patents eg Reckitt and CSD500 a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product. The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered for sale | lbo | |
16/8/2022 12:07 | She is spouting more BS | j777j | |
16/8/2022 12:05 | The market for erectile dysfunction One in five men suffers from erectile dysfunction worldwide3. Erectile dysfunction (ED) is closely linked to age and a number of co-morbidities exist such as obesity, diabetes and heart disease with the incidence of erectile dysfunction expected to increase to 322 million by 20254. Erectile dysfunction can result from organic or psychological causes and is increasingly affecting younger men who can also suffer from performance anxiety due to social pressure and false expectations from easy access to pornography. Erectile dysfunction can lead to low self-esteem, lack of confidence and depression. The detrimental impact on partners and relationships is well documented and acknowledged by the medical community. The discovery and approval of the PDE5i’s to treat ED over 20 years ago (such as Viagra® and Cialis®) not only revolutionised available treatments for men with ED but also dramatically increased awareness in the general public of this significant problem | j777j |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions